Drug Resistance, ViralAnti-HIV AgentsAnti-Retroviral AgentsHIV InfectionsHIV-1Drug Resistance, Multiple, ViralAntiretroviral Therapy, Highly Activepol Gene Products, Human Immunodeficiency VirusReverse Transcriptase InhibitorsHIV Reverse TranscriptaseCD4 Lymphocyte CountHIV ProteaseViral LoadMutationGenotypeDrug ResistanceDrug Resistance, NeoplasmHIV Protease InhibitorsDrug Resistance, MicrobialDrug Resistance, MultipleZidovudineBenzoxazinesNevirapineDrug Resistance, BacterialHIVInfectious Disease Transmission, VerticalAcquired Immunodeficiency SyndromeIndinavirLopinavirRitonavirOrganophosphonatesStavudineLamivudineDrug Therapy, CombinationNelfinavirHIV Fusion InhibitorsRNA, ViralPregnancy Complications, InfectiousPyrimidinonesAdenineDrug Resistance, Multiple, BacterialTreatment FailureSouth AfricaMicrobial Sensitivity TestsIntegrase InhibitorsAntitubercular AgentsMedication AdherenceDidanosineUgandaAIDS-Related Opportunistic InfectionsP-GlycoproteinSaquinavirHIV-Associated Lipodystrophy SyndromeDrug Resistance, FungalCohort StudiesHIV Integrase InhibitorsHIV SeropositivityViremiaPatient ComplianceVirus ReplicationTreatment OutcomeDideoxynucleosidesMolecular Sequence DataAnti-Bacterial AgentsDrug MonitoringAfrica South of the SaharaDisease ResistanceSequence Analysis, DNATime FactorsAntiviral AgentsDrug InteractionsGenes, polCD4-Positive T-LymphocytesOxazinesCyclohexanesVascular ResistanceMalawiMutation, MissenseZimbabwePregnancyTuberculosis, Multidrug-ResistantHIV Wasting SyndromeDeveloping CountriesDrug Administration SchedulePrevalencePyrrolidinonesDrug CombinationsPhenotypeProtease InhibitorsPlasmaTuberculosisLipodystrophyCommission on Professional and Hospital ActivitiesProspective StudiesDrugs, GenericAntineoplastic AgentsRetrospective StudiesZalcitabineRisk FactorsAntimalarials